Pnd155 - Reduced Relapse Rates and Improved Quality of Life for Relapsing-Remitting Multiple Sclerosis (Rrms) Patients Treated With Natalizumab vs Injectable Therapies

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.2903
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy